Introduction {#s1}
============

Under the control of a complex bidirectional signaling program ([@bib20]; [@bib22]; [@bib36]; [@bib37]), oligodendrocytes (OLs) encase central nervous system (CNS) axons with myelin, a highly organized and compacted multi-membrane structure. Myelination allows rapid transmission of action potentials and preserves axonal integrity by multiple mechanisms, including metabolic support by OLs ([@bib17]; [@bib27]; [@bib49]). Thus, loss of myelin in diseases of diverse etiology, such as in multiple sclerosis, ultimately results in axonal degeneration and clinical deterioration of affected patients ([@bib16]; [@bib36]; [@bib42]). During postnatal development, OL progenitor cells (OPCs) undergo a tightly orchestrated differentiation program leading to mature OLs that contact axons and wrap them with myelin ([@bib36]). A significant population of OPCs remains resident in the adult CNS, designated adult OPCs (aOPCs) ([@bib12]; [@bib16]). Upon a demyelinating injury, aOPCs are activated, migrate to the lesion site, proliferate, undergo differentiation, and mature into OLs that remyelinate axons. Hence, aOPCs-derived OLs substitute for pre-existing ones which are lost upon demyelination ([@bib10]; [@bib16]). However, this program often fails in myelin-defective lesions leaving axons particularly vulnerable. While a number of exogenous and endogenous factors are known to restrict the regenerative potential of aOPCs ([@bib16]; [@bib34]), the roles of modulators of their metabolic state remain largely unknown.

Myelin is characterized by an exceptionally high lipid content (\~80% of dry weight) ([@bib8]; [@bib36]; [@bib46]). Fatty acids (FAs) are fundamental building blocks for both glycolipids and phospholipids, which comprise the largest proportion of myelin membrane lipids ([@bib18]). FAs can be acquired from the pool present in the circulation due to dietary intake (essential and non-essential FAs), through horizontal flux from adjacent cells (essential and non-essential FAs), or are cell-endogenously synthesized (non-essential FAs) ([@bib6]; [@bib11]). However, the relative contribution of uptake versus synthesis to the final pool of FAs in OLs at different stages of differentiation remains to be determined.

The mTORC1-SCAP signaling axis regulates a plethora of lipogenic pathways via cleavage of Sterol Regulatory Element-Binding Proteins (SREBPs). These transcription factors are major modulators of FA and cholesterol metabolism ([@bib24]; [@bib38]), including in OLs ([@bib6]). Accordingly, depletion of mTOR ([@bib53]), the functionally required mTORC1 subunit Raptor ([@bib2]; [@bib26]) or SCAP ([@bib6]) in OLs causes reduced radial growth of myelin, mimicking the phenotype triggered by depletion of the SREBP-downstream target squalene synthase, an enzyme required for cholesterol synthesis ([@bib43]). Genetic depletion of Raptor and SCAP in OLs results also in reduced expression of FA synthase (FASN) ([@bib6]; [@bib26]) -- the enzyme responsible for the synthesis of the 16-carbon palmitic acid that is used as substrate for subsequent synthesis of longer FAs ([@bib11]). However, the functional role of endogenous FA synthesis in OL differentiation and CNS myelination, and how diminished FASN expression impacts upon the observed mTORC1/SCAP-knockout phenotypes, is not clear.

We previously found that de novo FA synthesis is essential for correct onset of myelination by Schwann cells, the myelinating cells of the peripheral nervous system (PNS) ([@bib35]). In the present study, we have tested whether OLs rely also on endogenous FA synthesis for developmental myelination. Furthermore, we investigated whether remyelination after injury depends on FA synthesis by OLs. In development, we addressed this question by genetically depleting FASN in the OL lineage of transgenic mice. To analyze the role of endogenous FA synthesis in remyelination of adults, we deleted FASN specifically from aOPCs and their progeny, in conjunction with a focal demyelinating spinal cord lesion using the well-established lysolecithin gliotoxin-injection model ([@bib3]). Our data reveal that endogenous FA synthesis in OLs is required for correct CNS myelination in development and essential for efficient remyelination in adulthood.

Results {#s2}
=======

Depletion of FASN in oligodendrocytes {#s2-1}
-------------------------------------

OLs have the capacity to cover numerous axons with multiple membrane layers to form myelin ([@bib36]). Thus, we hypothesized that OLs may depend on endogenous FASN-driven FA synthesis for myelin production. Indeed, OLs transcribe FASN at high levels (<http://web.stanford.edu/group/barres_lab/cgi-bin/igv_cgi_2.py?lname=Fasn>) ([@bib55]). To test our hypothesis, we used mouse genetics to ablate FASN specifically in the OL lineage. Conditionally mutant *Fasn*^lox/lox^ mice ([@bib7]) were crossed with mice expressing Cre recombinase under the control of *Olig2* gene regulatory elements ([@bib47]) ([Figure 1a](#fig1){ref-type="fig"}). The resulting *Fasn* mutants were viable, fertile and born according to Mendelian distribution. Loss of FASN expression was confirmed by immunohistochemistry in differentiated (CC1+) OLs of postnatal day (P) 14 mutants in spinal cord white matter ([Figure 1b,c](#fig1){ref-type="fig"}), in agreement with highly efficient recombination in OL lineage cells as monitored by inclusion of the Cre-dependent reporter *Rosa26-loxPstoploxP-YFP* allele ([@bib50]) ([Figure 1---figure supplement 1a,b](#fig1s1){ref-type="fig"}). Comparable loss of FASN was also found in the gray matter ([Figure 1---figure supplement 2a,b](#fig1s2){ref-type="fig"}). Note that large motoneurons in the ventral horn showed strong FASN expression, which was retained in mutant mice ([Figure 1---figure supplement 2a,b](#fig1s2){ref-type="fig"}).

![Generation of mutant mice lacking FASN in the oligodendrocyte lineage.\
(**a**) Experimental strategy of conditional *Fasn* allele inactivation upon *Olig2*-driven Cre expression in vivo. (**b**) Schematic of thoracic spinal cord. Square insert 'c': White matter (WM) where subsequent immunostaining images were acquired. GM = gray matter (**c**) Representative immunostaining of cross-sectioned spinal cord from P14 CT and cMU mice, *n* = 3 mice examined for each, CT and cMU. Prominent cytoplasmic FASN expression in differentiated OLs (CC1+; examples indicated by arrowheads) in CT, but not in cMU. Nuclear marker: DAPI. Scale bars: 20 μm. CT* =* control, cMU = conditional mutant, GM = gray matter, WM = white matter.](elife-44702-fig1){#fig1}

FASN is dispensable for proliferation and differentiation along the oligodendrocyte lineage {#s2-2}
-------------------------------------------------------------------------------------------

Before OLs reach the myelinating stage, their progenitors (OPCs) need to proliferate, differentiate and mature. In some proliferating cells such as in cancer and neuronal progenitors, FASN activity is required to support increased metabolic demands ([@bib11]; [@bib23]). Thus, we analyzed OL proliferation by EdU incorporation but found no detectable differences between mutants and controls at both P4 and P10 ([Figure 2a,b](#fig2){ref-type="fig"}). Next, we addressed whether lack of FASN may affect differentiation along the OL lineage during development. Initial immunohistochemical analyses revealed marginal (if any) FASN expression in white matter OPCs (PDGFRα+ cells) of the P14 spinal cord ([Figure 2---figure supplement 1a](#fig2s1){ref-type="fig"}), compared to high levels in differentiated OLs (CC1+ cells) ([Figure 2---figure supplement 1a](#fig2s1){ref-type="fig"}). Further comparative analyses of mutant and control mice yielded no significant differences in the percentages of OPCs (PDGFRα+ Olig2+) ([Figure 2---figure supplement 1b,c](#fig2s1){ref-type="fig"}), total OL lineage cells (Olig2+) ([Figure 2c,d and e](#fig2){ref-type="fig"}) and differentiated OLs (CC1+ Olig2+) ([Figure 2c,d and e](#fig2){ref-type="fig"}) in spinal cord white matter at P4, P10 and P14. Taken together, these data indicate that FASN is not required for correct proliferation and differentiation of the OL lineage to CC1+ cells during postnatal development.

![De novo fatty acid synthesis is not required to achieve correct numbers of oligodendrocyte lineage cells during development.\
(**a**) Representative immunostaining of ventral white matter in cross-sectioned spinal cords of P4 and P10 mice identifying proliferating (EdU+) OLs (Olig2+; examples indicated by arrowheads), *n* = 3 mice for each, CT and cMU. Nuclear marker: DAPI. Scale bar: 50 μm, applying to entire panel. (**b**) Corresponding graphs to (**a**) with quantification of percentage of proliferating OLs (EdU+ Olig2+) over total number of OLs (Olig2+) in spinal cord white matter of CT and cMU mice at P4 and P10. Data points represent *n* = 3 mice for each, CT and cMU; random fields of both dorsal and ventral white matter of 4 sections quantified per animal, with at least 83 Olig2+ cells quantified per section (unpaired two-tailed two sample Student's t-test; at P4: cMU vs. CT, p*=*0.6876, *t =* 0.4326; P10: cMU vs. CT, p*=*0.5448, *t =* 0.6608). (**c**) Representative immunostaining of ventral white matter in cross-sectioned spinal cords from P4, P10, and P14 mice identifying differentiated OLs (CC1+; examples indicated by arrowheads), OLs (Olig2+) and total number of cells (DAPI+), *n* = 3 mice for each, CT and cMU at P4 and P10, *n* = 5 mice for each, CT and cMU at P14. Nuclear marker: DAPI. Scale bar: 50 μm, applying to entire panel. (**d, e**) Corresponding graphs to (**c**) with quantification of percentage of total OLs (Olig2+) (**d**) and differentiated OLs (CC1+ Olig2+) (**e**) over total number of cells (DAPI+), in the spinal cord white matter of CT and cMU mice at P4, P10 and P14. Data points represent *n* = 3 mice for each, CT and cMU at P4 and P10, and *n* = 5 mice for each, CT and cMU at P14. Random fields of both dorsal and ventral white matter of at least 3 sections quantified per animal, with at least 83 Olig2+ cells quantified per section (unpaired two-tailed two sample Student's t-test; % Olig2+/DAPI+ at P4: cMU vs. CT, p*=*0.8280, *t =* 0.2319; at P10: cMU vs. CT, p*=*0.6694, *t =* 0.46; at P14: cMU vs. CT, p*=*0.3340, *t =* 1.028; % CC1+ Olig2+ / DAPI+ at P4: cMU vs. CT, p*=*0.3405, *t =* 1.081; at P10: cMU vs. CT, p*=*0.8490, *t =* 0.2031; at P14: cMU vs. CT, p*=*0.2061, *t =* 1.376). Bars represent mean ±SEM. CT* =* control, cMU = conditional mutant.](elife-44702-fig2){#fig2}

De novo fatty acid synthesis is critical for accurate CNS myelination, including radial myelin growth {#s2-3}
-----------------------------------------------------------------------------------------------------

Based on the observed high levels of FASN expression in differentiated (CC1+) OLs, we addressed next whether these cells rely on endogenous FA synthesis to myelinate. Thus, we performed EM ultrastructural morphological analysis of the ventral spinal cord white matter from control and mutant mice at P14 ([Figure 3](#fig3){ref-type="fig"}). We found that mutant mice exhibited more axons not encased by myelin compared to controls (69.57 ± 3.75% in mutants vs. 53.56 ± 2.37% in controls) ([Figure 3a,b](#fig3){ref-type="fig"}). Moreover, g-ratio analysis (i.e. ratio of axon to fiber (axon + myelin) diameter) revealed that mutant myelinated axons had overall thinner myelin compared to controls ([Figure 3c](#fig3){ref-type="fig"}). These data were confirmed by analysis of the correlation of g-ratio and fiber diameter with axon diameter ([Figure 3d,e](#fig3){ref-type="fig"}). To understand whether lack of FASN resulted in persistently reduced myelination of axons, we compared the ultrastructural morphology of white matter of the ventral spinal cord of mutant versus control mice at P180. Although myelination progressed in both cases, a higher percentage of not-yet myelinated axons persisted in the spinal cord white matter of mutant mice (15.21 ± 2.92% in mutants vs. 6.59 ± 1.01% in controls) ([Figure 3g](#fig3){ref-type="fig"}). In addition, marked hypomyelination of mutant axons also persisted ([Figure 3f](#fig3){ref-type="fig"}, arrows), confirmed by g-ratio analysis ([Figure 3h,i and j](#fig3){ref-type="fig"}). We conclude that endogenous FA synthesis in OLs is critical for accurate myelination in the spinal cord, including efficient myelin growth. Our findings may reflect that lack of endogenous FA synthesis limits total myelin production of each mutant OL and/or the number of myelin sheaths that can be generated. Other contributing factors to the mutant OL phenotype might include altered timing in the onset of individual myelin sheath formation.

![De novo fatty acid synthesis by oligodendrocytes is essential to achieve accurate myelination in the spinal cord.\
(**a**) Representative EM images of P14 control (CT, **a' and a''**) and conditional mutant (cMU, **b' and b''**) white matter from the ventral funiculi of lumbar spinal cords. cMUs show more naked axons, not-yet enwrapped by myelin, when compared to CTs. cMUs also display thinner myelin (examples indicated by arrows). Scale bars: 2 μm. (**b**) Corresponding graph with quantification of percentage of not myelinated axons at P14. Data points represent *n* = 3 mice for each, CT and cMU, with at least 590 axons quantified per animal in random fields selected in the same anatomical area (unpaired two-tailed two sample Student's t-test; at P14: cMU vs. CT, p*=*0.0225, *t =* 3.614), \*p\<0.05. (**c**) Overall hypomyelination at P14 in cMU as shown by g-ratio analysis. Data points represent *n* = 3 mice for each, CT and cMU (unpaired two-tailed two sample Student's t-test; at P14: cMU vs. CT, p*=*0.0025, *t =* 6.731), \*\*p\<0.01. (**d, e**) Linear correlation of g-ratio versus axon diameter (**d**) and of fiber diameter versus axon diameter (**e**), in the ventral white matter spinal cord of cMU compared to CT at P14. 100 myelinated axons per mouse analyzed in random fields selected in the same anatomical area, *n* = 3 mice for each, CT and cMU. (**f**) Representative EM images of P180 CT and cMU white matter from ventral funiculi of lumbar spinal cords. cMUs show more naked axons (false colored in orange) compared to CTs. cMU axons are encased by thinner myelin (examples indicated by arrows) compared to CTs. Scale bars: 5 μm. (**g**) Corresponding graph with quantification of percentage of not myelinated axons at P180. Data points represent *n* = 3 mice for each, CT and cMU, with at least 220 axons quantified per animal, in random fields selected in the same anatomical area (unpaired two-tailed two sample Student's t-test; at P180: cMU vs. CT, p*=*0.0493, *t =* 2.791), \*p\<0.05. (**h**) Overall hypomyelination at P180 in cMU compared to CT, as shown by g-ratio analysis. Data points represent *n* = 3 mice for each, CT and cMU (unpaired two-tailed two sample Student's t-test; at P180: cMU vs. CT, p*=*0.0027, *t =* 6.651), \*\*p\<0.01. (**i, j**) Linear correlation of g-ratio versus axon diameter (**i**) and of fiber diameter versus axon diameter (**j**), in the ventral white matter spinal cord of cMU compared to CT at P180. At least 65 myelinated axons per mouse analyzed in random fields selected in the same anatomical area, *n* = 3 mice for each, CT and cMU. Bars represent mean ±SEM. CT* =* control, cMU = conditional mutant.](elife-44702-fig3){#fig3}

To examine whether anatomically differently located OLs are similarly dependent on endogenous FA synthesis, we extended our study to the optic nerve. As observed in the spinal cord, high recombination efficiency in OL lineage cells was also found in this structure ([Figure 3---figure supplement 1a,b](#fig3s1){ref-type="fig"}). In line with our findings in the spinal cord, P14 optic nerves of mutant mice displayed a higher percentage of axons not-yet encased by myelin compared to controls (84.08 ± 0.33% in mutants vs. 75.68 ± 0.77% in controls) ([Figure 3---figure supplement 2a,b](#fig3s2){ref-type="fig"}). Although the onset of myelination progressed in both mutants and controls, also P180 mutant optic nerves retained more axons not encased by myelin (21.16 ± 5.1% in mutants vs. 4.29 ± 1.6% in controls) ([Figure 3---figure supplement 2f](#fig3s2){ref-type="fig"}, false colored, and g). Overall, no significant hypomyelination was detectable in optic nerves of mutant mice in early development (P14) ([Figure 3---figure supplement 2c,d and e](#fig3s2){ref-type="fig"}). Analysis of P180 optic nerves revealed, however, that mutant OLs failed to support ongoing myelin growth accurately, resulting in pronounced hypomyelination in adulthood ([Figure 3---figure supplement 2f](#fig3s2){ref-type="fig"}). This observation was confirmed by overall g-ratio quantification ([Figure 3---figure supplement 2h](#fig3s2){ref-type="fig"}) and correlation analyses of g-ratio and fiber diameter versus axon diameter ([Figure 3---figure supplement 2i,j](#fig3s2){ref-type="fig"}). We conclude that FASN activity in OLs is required for accurate myelination also in the optic nerve, albeit with subtle differences to the spinal cord.

Since the corpus callosum is often explored in myelin research, we examined also this brain region in the adult. Similar to our findings in the spinal cord and in the optic nerve, an increased fraction of axons that were not enwrapped by myelin was detected in the corpus callosum of P180 mutant mice (72.27 ± 0.98% in mutants vs. 63.53 ± 2.41% in controls) ([Figure 3---figure supplement 3a,b](#fig3s3){ref-type="fig"}). In addition, myelinated axons displayed relatively thinner myelin in mutants, as indicated by the higher g-ratio values compared to controls ([Figure 3---figure supplement 3a,c](#fig3s3){ref-type="fig"}) and confirmed by scatter plots of g-ratio and fiber diameter versus axonal diameter ([Figure 3---figure supplement 3d,e](#fig3s3){ref-type="fig"}).

Taken together, our studies of different CNS regions revealed that endogenous FA synthesis by OLs is required for correct myelination in various areas. More detailed comparisons require further investigations, including complementary approaches to alleviate technical limitations. Such examinations may well uncover more subtle variations between these regions, possibly relating to the physiological context of each environment, including local differences in astrocyte coupling, or potential intrinsic differences between oligodendrocyte lineage cells ([@bib13]; [@bib32]).

De novo fatty acid synthesis contributes to the stability of myelinated axons and correct CNS myelin lipid composition {#s2-4}
----------------------------------------------------------------------------------------------------------------------

A further characteristic feature in spinal cord tissue of P14 mutant mice were some aberrant vacuolated myelin-axon profiles ([Figure 4a](#fig4){ref-type="fig"}), confirmed by quantification (3.81 ± 0.15% in mutants vs. 0.25 ± 0.08% in controls) ([Figure 4b](#fig4){ref-type="fig"}). These structures resembled those observed in the PNS when Schwann cells lack FASN ([@bib35]). Irregular myelin ([Figure 4a](#fig4){ref-type="fig"}, arrowheads) was often surrounding axons which appeared compressed ([Figure 4a](#fig4){ref-type="fig"}, asterisks). Similarly, examination of optic nerves revealed a comparable increase in anomalous myelin-axon profiles in mutant mice (5.41 ± 1.0% in mutants vs. 0.75 ± 0.19% in controls) ([Figure 4---figure supplement 1a,b](#fig4s1){ref-type="fig"}).

![De novo fatty acid synthesis by oligodendrocytes is required to maintain structural stability of myelinated axons.\
(**a**) Exemplary EM images of aberrant myelin-axon profiles showing vacuolation (examples indicated by arrowheads) in the ventral white matter of spinal cords of P14 cMUs. Where identifiable, axons associated with aberrant structures are indicated by asterisks. Scale bars: I = 5 µm, II = 2 µm, III = 2 µm, IV = 2 µm, V = 5 µm, VI = 2 µm, VII = 2 µm. (**b**) Corresponding graph with quantification of the percentage of aberrant myelin-axon profiles. Data points represent *n* = 3 mice for each, CT and cMU (unpaired two-tailed two sample Student's t-test; at P14: cMU vs. CT p\<0.0001, *t =* 21.16), \*\*\*p\<0.001. At least 8300 axons per mouse analyzed in random fields selected in the same anatomical area. (**c**) Total FA composition of myelin purified from spinal cords of P60 CT and cMU mice, divided in non-essential FAs (NEss), conditional-essential FAs (Cond Ess) and essential FAs (Ess). Data points represent *n* = 3 mice for CT and *n* = 4 mice for cMU (unpaired two-tailed two sample Student's t-test; NEss: cMU vs. CT, p*=*0.2609, *t =* 1.267; Cond Ess: cMU vs. CT, p*=*0.6625, *t =* 0.4635; Ess: cMU vs. CT, p*=*0.4435, *t =* 0.8317). (**d**) Quantification of the most abundant FAs found in myelin purified from spinal cords of CT and cMU mice. Data points represent *n* = 3 mice for CT and *n* = 4 mice for cMU (unpaired two-tailed two sample Student's t-test; Oleic: cMU vs. CT, p*=*0.2525, *t =* 1.293; Palmitic: cMU vs. CT, p*=*0.7377, *t =* 0.3542; Stearic: cMU vs. CT, p*=*0.4966, *t =* 0.7328). (**e, f, g**) Content of ceramides (**e**), cerebrosides (**f**) and sphingomyelin (**g**) in myelin isolated from spinal cords of cMU compared to CT mice. Data points represent *n* = 4 mice for each, CT and cMU (unpaired two-tailed two sample Student's t-test; ceramides: cMU vs. CT, p*=*0.2822, *t =* 1.181; cerebrosides: cMU vs. CT, p*=*0.2722, *t =* 1.209; sphingomyelin: cMU vs. CT, p*=*0.2310, *t =* 1.333). (**h, i, j, k**) Total content of phosphatidylinositols (PI), phosphatidylserines (PS), phosphatidylcholines (PC) and phosphatidylethanolamines (PE) in myelin isolated from spinal cords of CT and cMU mice. Data points represent *n* = 4 mice for each, CT and cMU (unpaired two-tailed two sample Student's t-test; PI: cMU vs. CT, p*=*0.1765, *t =* 1.532; PS: cMU vs. CT, p*=*0.0031, *t =* 4.784; PC: cMU vs. CT, p*=*0.2698, *t =* 1.216; PE: cMU vs. CT, p*=*0.7236, *t =* 0.3706), \*\*p\<0.01. Bars represent mean ±SEM. CT* =* control, cMU = conditional mutant.](elife-44702-fig4){#fig4}

Since FAs are key structural components of cellular membranes, we investigated the lipid composition of myelin in mutant mice that lack FA synthesis in OLs compared to controls. To this end, we quantified FAs and FA-derived lipid classes in myelin purified from spinal cords of P60 mice. No significant alterations were detectable in essential (diet-derived), conditional-essential (derived from essential) and non-essential FAs ([Figure 4c](#fig4){ref-type="fig"}, [Figure 4---figure supplement 2a](#fig4s2){ref-type="fig"}) of mutants. Furthermore, we found no difference in the content of palmitate, the direct product of FASN enzymatic activity in mutant vs. control myelin ([Figure 4d](#fig4){ref-type="fig"}). Myelin from spinal cords of mutant mice contained also similar amounts of ceramides ([Figure 4e](#fig4){ref-type="fig"}, [Figure 4---figure supplement 2b](#fig4s2){ref-type="fig"}), cerebrosides ([Figure 4f](#fig4){ref-type="fig"}, [Figure 4---figure supplement 2c](#fig4s2){ref-type="fig"}), and sphingomyelin ([Figure 4g](#fig4){ref-type="fig"}, [Figure 4---figure supplement 2d](#fig4s2){ref-type="fig"}) compared to controls. Besides some minor alterations ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}), strikingly elevated total levels of phosphatidylserines were found in mutants compared to controls (393.5 ± 25.53 in mutants vs. 269.6 ± 4.38 in controls, pmol/mg of proteins) ([Figure 4i](#fig4){ref-type="fig"}, [Figure 4---figure supplement 2g](#fig4s2){ref-type="fig"}). We conclude that lack of endogenous FA synthesis in OLs has a modest influence on the resulting lipid composition of myelin.

Transcriptome analysis of optic nerves of *Fasn* mutant mice reveals oligodendrocyte defects in late stages of maturation, including myelination {#s2-5}
------------------------------------------------------------------------------------------------------------------------------------------------

Our results obtained so far indicated that FASN is critical for timely onset of OLs myelination and subsequent radial growth of CNS myelin, but does not play a major role in OL lineage progression based on expression of Olig2, PDGFRα, and CC1 as analytic markers. It is well known, however, that aside from being building blocks for different lipid species, FAs play other key roles such as a source of energy by oxidation ([@bib31]), through palmitoylation of proteins ([@bib39]; [@bib45]), and by modulating transcriptional networks ([@bib1]). In this context, we have previously identified activation of PPARγ as a mediator of FASN in triggering onset of PNS myelination ([@bib35]). In view of these findings, molecular alterations due to lack of FASN in the OL lineage appeared likely. Given that we had not observed significant alterations in OL differentiation up to the CC1+ stage, such potential changes are predicted to reflect functions of OL-derived FASN in the transition of CC1+ OLs to the final stages of maturation up to myelination completion. We addressed this issue by comparing the optic nerve transcriptome of P14 mutant and control mice ([Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}). In line with our morphological findings, Metacore enrichment analysis revealed repression of GeneOntology Processes associated with development of the nervous system, OL differentiation, and myelination ([Figure 5a,b](#fig5){ref-type="fig"}). A more detailed Metacore Pathway analysis highlighted downregulation of known regulatory axes of OL maturation and myelination, including cytoskeleton proteins, cell-cell and ECM-cell interactions, as well as epigenetic and transcriptional regulation ([Figure 5a,b](#fig5){ref-type="fig"}). To explore these dysregulations further, we compared them to OLs single cell transcriptomic data ([@bib32]). This comparison revealed that mutant optic nerves displayed increased expression of a subset of transcripts enriched in mature OLs (MOL 1--6 in ref. [@bib32]) such as Klk6, Sepp1, and Glul. In parallel, reduced expression of several transcripts enriched in myelin-forming OLs (MFOL1/2 in ref. [@bib32]) including Ctps, Sirt2, Gpr17, Olig1, Mag and Mobp was identified. Following up on these findings by a candidate approach, we detected also reduced expression of transcripts encoding well known myelin-associated proteins such as PLP1, MBP and CNP, and of major regulators of OLs including Sox10, Sox8, and Myrf ([@bib4]; [@bib21]; [@bib29]; [@bib52]) ([Figure 5c](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Combined with our previous findings, the dysregulated molecular fingerprint revealed by these data is consistent with a functional role for FASN in late OL maturation and myelination. However, the impaired myelination in mutant mice may also contribute to the transcriptome differences compared to controls.

![Transcriptome analysis of optic nerves of *Fasn* mutant mice reveal oligodendrocyte defects in late stages of maturation, including myelination.\
(**a, b**) GeneOntology analysis depicting biological processes affected by down-regulated (**a**) and up-regulated (**b**) transcripts in P14 optic nerves of mutant (cMU) mice. Metacore Pathway analysis showing pathways affected by downregulated (**a**) and upregulated (**b**) transcripts in P14 optic nerves of cMU mice. Data points represent the count of regulated transcript for each category and pathway. (**c**) Heat map of RNA-seq data of CT and cMU optic nerves at P14, depicting Fasn and selected down- and up-regulated modulators of OL differentiation, maturation and myelination (FDR \< 0.05). Markers identified by comparison with OLs single cell sequencing data ([@bib32]) are marked with an asterisk. *n* = 3 mice for cMU, *n* = 4 mice for CT. CT* =* control, cMU = conditional mutant, MFOLs = myelin-forming oligodendrocytes, MOLs = mature oligodendrocytes ([@bib32]).\
10.7554/eLife.44702.016Figure 5---source data 1.Expressed transcripts in optic nerves from control and cMU mice at P14.](elife-44702-fig5){#fig5}

Increased dietary intake of lipids can partially rescue lack of fatty acid synthesis by oligodendrocytes {#s2-6}
--------------------------------------------------------------------------------------------------------

Increasing dietary intake of lipids was unable to rescue lack of endogenous FA synthesis by Schwann cells in PNS myelination, instead being surprisingly detrimental ([@bib35]). To investigate whether such a treatment could rescue myelination if OLs are deficient in FA synthesis, we fed mutant and control mice either a 60% high fat diet (HFD; % of caloric intake from fat, enriched in palmitic acid; complete FA content in Materials and methods), previously shown to be capable of rescuing diminished lipogenesis in astrocytes in vivo ([@bib5]; [@bib6]), or a standard diet (STD; complete FA content in Materials and methods). Pregnant females and subsequently born pups were fed with the different diets from E14 up to P40, the time of analysis ([Figure 6a](#fig6){ref-type="fig"}). We found that the HFD regimen lead to improved myelin radial growth in the spinal cord of mutant mice compared to mutant mice fed with STD ([Figure 6b,c and d](#fig6){ref-type="fig"}). There were no significant effects of HFD on radial myelin growth in control mice ([Figure 6b,c and d](#fig6){ref-type="fig"}). Myelinated fibers in the spinal cord of mutant mice treated with HFD were still hypomyelinated compared to those of control mice under HFD or STD, but less so than those of mutant mice under STD ([Figure 6b,c and d](#fig6){ref-type="fig"}). We conclude that lack of endogenous FA synthesis in OLs during development can be partially compensated by increasing dietary lipid intake.

![Increasing dietary lipid intake can partially compensate defects in radial myelin growth caused by lack of endogenous fatty acid synthesis in oligodendrocytes.\
(**a**) Scheme of the experimental design. (**b**) Exemplary EM micrographs of the ventral funiculus of the lumbar spinal cord from mutant (cMU) and control (CT) mice that were fed a standard (STD) or a high-fat (HFD) diet. Scale bars: 5 µm. (**c**) Linear correlation of g-ratio versus axon diameter. At least 84 myelinated axons analyzed per mouse, in random fields selected in the same anatomical area, from *n* = 3 mice for each, CT and cMU, STD and HFD. (**d**) Overall hypomyelination in cMU compared to CT fed STD at P40, and partial recovery of radial myelination in cMU fed with HFD, as shown by g-ratio analysis. Data points represent *n* = 3 mice for each, CT and cMU, STD and HFD (one-way Anova; Treatment: p\<0.0001, *F*~3,8~ = 113.2; with Sidak's multiple comparisons test; cMU STD vs. CT STD: p\<0.0001, *t =* 15.96; cMU HFD vs. CT HFD: p*=*0.0002, *t =* 8.597; CT HFD vs CT STD: p*=*0.7703, *t =* 1.339; MU HFD vs. MU STD: p*=*0.0019, *t =* 6.025), \*\*\*p\<0.001, \*\*p\<0.01. Bars represent mean ±SEM. STD = standard diet, HFD = high fat diet, CT* =* control, cMU = conditional mutant.](elife-44702-fig6){#fig6}

Depletion of fatty acid synthase in adult oligodendrocyte progenitors to study CNS remyelination {#s2-7}
------------------------------------------------------------------------------------------------

Following demyelination, new myelin is formed by aOPCs ([@bib10]; [@bib16]). To address the significance of FA synthesis in this process, we conditionally ablated the *Fasn* gene specifically in aOPCs of transgenic mice using tamoxifen-activatable Cre recombinase under the control of *Pdgfr*α gene regulatory elements ([@bib40]). Recombination also activated YFP expression via the Cre-dependent reporter *Rosa26-loxPstoploxP-YFP* allele ([@bib50]) that was included in both, induced mutants (i-cMU) and induced control (CT) mice. This experimental design allowed us to follow the fate of recombined cells ([Figure 7a](#fig7){ref-type="fig"}; [Figure 7---figure supplement 1a,b](#fig7s1){ref-type="fig"}). We then addressed how loss of FASN in aOPCs affects remyelination of a demyelinated focal lesion in the spinal cord, induced by injection of the gliotoxin lysolecithin (experimental setting schematized in [Figure 7b](#fig7){ref-type="fig"}). Such lesions undergo a stereotyped timed program of remyelination that is characterized by high proliferation of recruited aOPCs, followed by their differentiation into CC1+ OLs, OL maturation, and onset of remyelination within the first 10--14 days post lesion (dpl), which is largely completed by 21 dpl ([@bib14]; [@bib54]) ([Figure 7b](#fig7){ref-type="fig"}). Immunohistochemistry revealed high FASN expression in differentiated CC1+ aOPC-derived OLs in control mice at the lesion site 7 dpl ([Figure 7c,d](#fig7){ref-type="fig"}). As expected, this expression was lost in mutant mice ([Figure 7c,d](#fig7){ref-type="fig"}).

![Generation of tamoxifen-inducible *PdgfrαCreERT2:FASN-floxed* conditionally mutant mice.\
(**a**) Tamoxifen-mediated nuclear translocation of *Pdgfrα*-driven CreERT2 induces conditional *Fasn* allele inactivation (i-cMU) and expression of yellow fluorescent protein (YFP). (**b**) Timeline of de-/re-myelination experiments: Focal demyelination of the ventral spinal cord white matter was induced by injection of lysolecithin 4 weeks post-tamoxifen administration. The tissue was analysed 7, 10, 14, 21 and 56 days post-lysolecithin injection (dpl). (**c**) Schematic of lysolecithin-induced demyelinated focal lesion in the ventral funiculus of the thoracic spinal cord (level T12). Square insert indicates the area where immunostaining images were acquired. (**d**) Representative immunostainings of lesioned areas in cross-sectioned thoracic spinal cords from CT and i-cMU mice 7 dpl, *n* = 3 mice analyzed for each, CT and i-cMU. Note the prominent FASN expression in the cytoplasm of recombined aOPC-derived differentiated OLs (CC1+ YFP+ FASN+, examples indicated by arrowheads) in CT, but not in i-cMU (CC1+ YFP+ FASN-, examples indicated by dotted lines) lesions. Nuclear marker: DAPI. Scale bar: 20 μm, applies to entire panel. CT* =* control, i-cMU = inducible conditional mutant, dpl = days post-lysolecithin injection.](elife-44702-fig7){#fig7}

Fatty acid synthesis is required to sustain aOPC-derived oligodendrocytes during remyelination {#s2-8}
----------------------------------------------------------------------------------------------

To explore the role of FA synthesis in OLs during remyelination, we next analyzed FASN expression in aOPCs and the effects of its depletion on their differentiation following demyelination. Comparable to our developmental studies, we found only marginal expression (if any) of FASN in aOPCs located in acute lesions at 7 dpl ([Figure 8---figure supplement 1a](#fig8s1){ref-type="fig"}). Statistical analysis of immunohistochemical data revealed no significant difference between induced mutant and control mice in numbers of recombined aOPCs (YFP+ PDGFRα+ Olig2+) when data were analyzed over time at 7, 10, 14 and 21 dpl ([Figure 8---figure supplement 1b,c](#fig8s1){ref-type="fig"}). However, if mutants and controls were statistically compared at the individual time points, a modest but significant reduction in recombined aOPCs was apparent at 14 dpI and 21 dpl (unpaired two-tailed two sample Student's t-test; i-cMU vs. CT, at 14 dpl: p=0.0164, *t* = 3.027; at 21 dpl: p=0.041, *t* = 2.434). We conclude that FASN is mostly dispensable for building up and maintaining the pool of aOPCs at the lesion site, given that in our lesion model this pool is largely established at 10 dpI ([Figure 8---figure supplement 1b,c](#fig8s1){ref-type="fig"}). In line with this interpretation, and similar to the developmental situation, we also found that FASN is not essential for early proliferation of OL lineage cells (Olig2+) as tested by Ki67 immunohistochemistry at 7 dpl ([Figure 8---figure supplement 2a,b](#fig8s2){ref-type="fig"}).

Next, we examined whether FASN is required during differentiation and maturation of aOPCs into myelinating OLs following demyelination. We found no difference in the number of recombined total (Olig2+ YFP+) and differentiated (CC1+ Olig2+ YFP+) aOPC-derived OLs in mutant and control mice during early differentiation (7 dpI and 10 dpl) ([Figure 8a,b and c](#fig8){ref-type="fig"}). However, the number of both recombined total (Olig2+ YFP+) and differentiated (CC1+ Olig2+ YFP+) OLs was substantially lower in mutants compared to controls when remyelination was ongoing (14 dpl), with no major recovery at 21 dpl (Olig2+ YFP+ cells per area (mm^2^) at 14 dpl: 98.4 ± 13.71 in mutants vs. 294.60 ± 28.05 in controls; at 21 dpl: 108.10 ± 11.93 in mutants vs. 237.70 ± 22.55 in controls; CC1+ Olig2+ YFP+ cells per area (mm^2^) at 14 dpl: 45.18 ± 6.71 in mutants vs. 193.20 ± 11.73 in controls; at 21 dpl: 74.60 ± 5.00 in mutants vs. 183.00 ± 18.47 in controls) ([Figure 8a,b and c](#fig8){ref-type="fig"}). This impairment was present already at the onset of remyelination (12 dpl; [Figure 8---figure supplement 3a,b and c](#fig8s3){ref-type="fig"}), suggesting that OL death might be involved. Cleaved caspase 3 (cC3) immunostaining at 11 dpl did not detect a significant increase in the percentage of apoptotic differentiated recombined OLs (cC3+ CC1+ YFP+) in lesions of mutants compared to controls ([Figure 8---figure supplement 3d,e](#fig8s3){ref-type="fig"}). However, we found such cells at very low frequency, contributing to a rather high variability between animals and limiting the power of our analysis and its interpretation. Thus, we assume that our inability to find an expected significant increase in cC3-associated OL cell death in mutants is likely due to either very fast removal of dying cells or cell death not marked by cC3-positivity, possibilities that we were unable to explore further due to technical limitations.

![De novo fatty acid synthesis is required for maintaining the adult oligodendrocyte progenitor-derived oligodendrocyte population during remyelination.\
(**a**) Representative immunostaining of lesions of control (CT) and inducible conditional mutant (i-cMU) mice on cross sections of ventral white matter of the spinal cord at 7, 10, 14 and 21 days post-lysolecithin injection (dpl), *n* = 5 mice for each, CT and i-cMU. Images depict recombined aOPC-derived differentiated OLs (CC1+ Olig2+ YFP+, examples indicated by arrowheads). Scale bar: 20 μm, applies to entire panel. (**b, c**) Corresponding graphs with quantification of (**b**) recombined OLs (Olig2+ YFP+) and (**c**) recombined aOPC-derived differentiated OLs (CC1+ Olig2+ YFP+) in lesion areas of ventral spinal cord white matter of CT and i-cMU mice at 7, 10, 14 and 21 dpl. Data were normalized per area. Data points represent *n* = 5 mice for each, CT and i-cMU. Lesion areas of at least 4 sections quantified per animal (2-way Anova; (**b**) Genotype: p\<0.0001*, F*~1,32~= 30.28; (**c**) Genotype: p\<0.0001*, F*~1,32~= 84.52; with Tukey's multiple comparisons test; (**b**) 7 dpl: i-cMU vs. CT, p*=*0.9829; 10 dpl: i-cMU vs. CT, p*=*0.6132; 14 dpl: i-cMU vs. CT, p\<0.0001; 21 dpl: i-cMU vs. CT, p*=*0.0071; (**c**) 7 dpl: i-cMU vs. CT, p*=*0.9971; 10 dpl: i-cMU vs. CT, p*=*0.0900; 14: i-cMU vs. CT, p\<0.0001; 21 dpl: i-cMU vs. CT, p\<0.0001), \*\*\*p\<0.001, \*\*p\<0.01. Bars represent mean ± SEM. CT* =* control, i-cMU = inducible conditional mutant, dpl = days post-lysolecithin injection.](elife-44702-fig8){#fig8}

Overall our data indicate a crucial role for FA synthesis in sustaining aOPC-derived OLs during remyelination. However, we cannot rule out that also the mild reduction in the number of aOPCs in mutants at 14 dpI and 21 dpl makes some contribution to the observed phenotype. In this context, we favor the interpretation that the observed decrease in CC1+ recombined OLs in mutant animals during remyelination may promote a mild reaction of aOPCs, potentially with the goal of some compensation. If the recombined cells cannot be sustained and die while differentiating from aOPCs towards myelinating oligodendrocytes, this may cause a slight reduction of the remaining numbers of recombined aOPCs. Alternatively, aOPCs may have intrinsic differences in their dependency on FASN compared to developmental OPCs with regard to survival. We consider this less likely given the low expression of FASN by developmental OPCs and aOPCs.

Fatty acid synthesis is essential for efficient CNS remyelination {#s2-9}
-----------------------------------------------------------------

Based on our findings, we next investigated whether the observed drop in differentiated OLs causes a failure of accurate remyelination in mutants. Thus, we analyzed the ultrastructural morphology of remyelinating spinal cord lesions by comparative EM as remyelinated axons can be distinguished by their relatively thin myelin compared to developmentally achieved myelination ([@bib16]). Consistent with the reduced number of differentiated CC1+ OLs present during the active remyelination phase at 14 dpl, we found that mutant mice displayed more axons not encased by myelin ([Figure 9a](#fig9){ref-type="fig"}, false colored) compared to control mice ([Figure 9a](#fig9){ref-type="fig"}). Quantification confirmed these observations (35.63 ± 3.42% demyelinated axons in mutants vs. 22.68 ± 1.58% in controls) ([Figure 9b](#fig9){ref-type="fig"}). Also at 21 dpl, only 8.24 ± 0.70% of axons remained demyelinated in control mice, compared to 18.00 ± 1.91% in mutants. At this time point, focal lesions approach their full remyelination potential ([@bib10]; [@bib16]). In agreement, further analysis of a later time point (56 dpl) revealed only a slight additional decrease in the percentage of demyelinated fibers in control mice to 5.58 ± 1.02% ([Figure 9b](#fig9){ref-type="fig"}). Similarly, this value decreased also in mutants to 12.04 ± 1.11% ([Figure 9b](#fig9){ref-type="fig"}). However, in direct comparison of controls and mutants at 56 dpI, mutants still retained a larger percentage of demyelinated axons (12.04 ± 1.11% in mutants vs. 5.58 ± 1.02% in controls) ([Figure 9b](#fig9){ref-type="fig"}). Remyelinated profiles of both control and mutant mice showed characteristically thin myelin ([Figure 9a](#fig9){ref-type="fig"}) ([@bib16]), with no significant difference detectable in the thickness of myelin by average g-ratio analysis ([Figure 9c](#fig9){ref-type="fig"}) and by linear correlation of g-ratio versus axon diameter ([Figure 9d](#fig9){ref-type="fig"}) at the sampled time points (14, 21 and 56 dpl). We conclude that FASN and consequently FA synthesis in OLs is essential for efficient remyelination in adult mice.

![De novo fatty acid synthesis is essential to achieve efficient remyelination in the spinal cord.\
(**a**) Representative EM images of lesions in the spinal cord of control (CT) and inducible conditional mutant (i-cMU) mice during remyelination at 14, 21 and 56 days post-lysolecithin injection (dpl). i-cMUs show persistently increased numbers of demyelinated axons (examples false colored in orange) compared to CTs up to 56 dpl. Scale bars: 3 μm. (**b**) Corresponding graphs with quantification of percentage of demyelinated axons within the remyelinated lesion area at 14, 21 and 56 dpl. Data points represent *n* = 3 mice for each, CT and i-cMU. The entire lesion area was quantified, at least 550 axons counted per animal (unpaired two-tailed two sample Student's t-test; 14 dpl: i-cMU vs. CT, p*=*0.0263, *t =* 3.439; 21 dpl: i-cMU vs. CT, p*=*0.0086, *t =* 4.803; 56 dpl: i-cMU vs. CT, p*=*0.0127, *t =* 4.290), \*p\<0.05, \*\*p\<0.01. (**c**) g-ratio analysis of remyelinated fibers at 14, 21 and 56 dpl in i-cMU compared to CTs. Data points represent *n* = 3 mice for each, CT and i-cMU (unpaired two-tailed two sample Student's t-test; 14 dpl: i-cMU vs. CT, p*=*0.1146, *t =* 2.011; 21 dpl: i-cMU vs. CT, p*=*0.3146, *t =* 1.149; 56 dpl: i-cMU vs. CT, p*=*0.1481, *t =* 1.789). (**d**) Linear correlation of g-ratio versus axon diameter in remyelinating lesions of i-cMU compared to CT mice, at 14, 21 and 56 dpl. At least 50 myelinated axons per mouse analyzed, *n* = 3 mice for each, CT and i-cMU. Bars represent mean ± SEM. CT* =* control, i-cMU = inducible conditional mutant, dpl = days post-lysolecithin injection.](elife-44702-fig9){#fig9}

Discussion {#s3}
==========

Oligodendrocytes require rapid access to large quantities of lipids over a short period of time to achieve accurate production of the considerable membrane mass required to myelinate multiple axons ([@bib8]; [@bib36]; [@bib46]). To which extent this demand is supported by endogenous synthesis in OLs and/or lipid uptake is not fully understood ([@bib8]; [@bib46]). In support of a critical role for OL-endogenous lipid biosynthesis, the mTORC1/SREBP signaling axis was suggested to be critical for efficient CNS myelination ([@bib6]; [@bib26]). Furthermore, OLs depend on cholesterol synthesis for efficient radial growth of myelin ([@bib43]). Postnatally, newly added cholesterol -- the major sterol present in myelin -- can only be synthesized within the CNS, while the other main myelin lipids share FAs as building blocks that might be either locally synthesized or taken up from the bloodstream ([@bib11]; [@bib18]). Here, we have addressed the need for FA synthesis in OLs by depleting FASN in transgenic mice. This multifunctional enzyme is responsible for the synthesis of palmitate, the substrate for the production of more complex FAs ([@bib11]; [@bib18]). We show that lack of FASN in OLs results in deficits in CNS myelination, including a decreased capacity for myelin to grow. Thus, OLs strictly depend on de novo endogenous FA synthesis to achieve normal myelination.

Another source for non-essential FAs, and the only source available for essential ones, is the uptake from the FA pool present in the circulation ([@bib18]). We have previously demonstrated that increasing dietary lipids by administering a HFD cannot ameliorate the dysmyelination resulting from lack of FASN in myelinating Schwann cells of the PNS ([@bib35]). Thus, we were somewhat surprised to find that the same HFD experimental regimen was able to achieve partial amelioration of the CNS hypomyelination caused by lack of FASN in OLs. Similarly, it has been shown that the HFD used in our study could partially substitute for the lack of SCAP in another CNS cell population, the astrocytes ([@bib5]; [@bib6]). The causative mechanisms for these differences between the PNS vs. CNS remain to be determined. Future studies will need to take into account that the two tissues appear to have evolved distinct compensatory mechanisms to deal with this situation. Specifically, adipocytes that are present in the layers surrounding peripheral nerves (i.e. epineurial adipocytes) can carry out lipolysis, potentially to provide supporting lipids when endogenous synthesis in Schwann cells fails ([@bib35]) or might become limiting. In contrast, the CNS contains astrocytes which can provide horizontal lipid flux to OLs ([@bib6]). However, the specifics of qualitative (i.e. which lipid species are involved) and quantitative contributions, both spatially and temporally, are challenging open research questions. In addition, the relevance of such mechanisms to the maintenance of homeostatic physiology and in disease situations remain important topics to be investigated.

Given the relevance of efficient remyelination as a drug target in diseases such as multiple sclerosis ([@bib9]; [@bib16]) and the currently clinically explored potential of biotin -- an important regulator of FA synthesis -- in multiple sclerosis treatment ([@bib48]), we were motivated to evaluate the significance of FA synthesis by OLs also in remyelination. To realize this goal, we used the focal lysolecithin-induced demyelinating-remyelinating lesion model in the spinal cord of transgenic mice after depleting FASN specifically in aOPCs. We show that de novo synthesis of FAs is crucial to sustain remyelinating aOPC-derived OLs and is ultimately required for successful remyelination. Specifically, we found that after being able to differentiate correctly, the number of aOPCs-derived OLs was substantially reduced in mutants compared to controls at onset of remyelination, persisting at later time points. Thus, endogenous FA synthesis appears to be pivotal to maintain survival of newly differentiated and mature aOPCs-derived OLs when myelination starts. At the myelin level, depletion of FASN in aOPCs and their progenies was associated with reduced numbers of remyelinated axons in mutants compared to controls from 14 dpl (first time point analyzed) up to 56 dpl (latest time point analyzed). This rather strong phenotype was not expected, since we anticipated that partial disruption of the blood-brain (-spinal cord) barrier in the lesioned CNS may lead to facilitated access of OLs to supplementary FA sources, that is from the pool of FAs in the blood, either directly or from increased horizontal flux from astrocytes ([@bib6]; [@bib44]). Possibly, saturation of molecules mediating FA-uptake and/or unknown regulatory mechanisms might restrict the FA uptake capacity of OLs not allowing full compensation for the lack of endogenous synthesis. Such mechanisms may also be differentially regulated in lesioned versus intact tissue. Future studies in this context should be aimed at achieving a detailed understanding of the molecular mechanisms that regulate synthesis and trafficking of FAs in the normal and diseased CNS, with a particular emphasis on OLs, astrocytes and blood vessels, including endothelial cells and pericytes. Such knowledge is expected to broaden our understanding of the fundamental mechanisms that regulate developmental myelination, pathological states in diseases, and remyelination after injury ([@bib8]; [@bib46]).

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                     Designation                                                     Source or reference                           Identifiers                                                                                   Additional\
  (species) or resource                                                                                                                                                                                                                         information
  --------------------------------- --------------------------------------------------------------- --------------------------------------------- --------------------------------------------------------------------------------------------- -----------------------------------------------------------
  Genetic reagent\                  *Fasnlox/lox*                                                   PMID:16054078                                 MGI:3765070                                                                                   Dr. Clay F.\
  (*M. musculus*)                                                                                                                                                                                                                               Semenkovich, Washington University, St. Louis USA

  Genetic reagent (*M. musculus*)   *PdgfraCreERT2*                                                 PMID:18849983                                 MGI:3832569                                                                                   Dr. William D. Richardson,\
                                                                                                                                                                                                                                                University College London, London UK

  Genetic reagent (*M. musculus*)   *Olig2Cre*                                                      Jackson Laboratory                            Stock\#:011103; MGI:3810299                                                                   PMID:18691547

  Genetic reagent (*M. musculus*)   *Rosa26-loxPstoploxP-YFP*                                       Jackson Laboratory                            Stock\#:006148; MGI:3621481                                                                   PMID:11299042

  Sequence-based reagent            Genotyping\                                                     PMID:29434029                                                                                                                               5\'-GGATAGCTGTGTAGTGTAACCAT-3'
                                    primer: Fasn forward                                                                                                                                                                                        

  Sequence-based reagent            Genotyping primer: Fasn reverse                                 PMID:29434029                                                                                                                               5'-GGTCACCCAGCAGGAAAGGGC- 3'

  Sequence-based reagent            Genotyping primer: Cre forward                                  PMID: 29434029                                                                                                                              5'-TTCCCGCAGAACCTGAAGATGTTCG-3'

  Sequence-based reagent            Genotyping primer: Cre reverse                                  PMID: 29434029                                                                                                                              5'-GGGTGTTATAAGCAATCCCCAGAAATG-3'

  Sequence-based reagent            Genotyping primer: Rosa26-loxPstoploxP-YFP forward              PMID: 28522536                                                                                                                              5'-AAAGTCGCTCTGAGTTGTTAT-3'

  Sequence-based reagent            Genotyping primer: Rosa26-loxPstoploxP-YFP reverse transgenic   PMID: 28522536                                                                                                                              5'-GCGAAGAGTTTGTCCTCAACC-3'

  Sequence-based reagent            Genotyping primer: Rosa26-loxPstoploxP-YFP reverse wildtype     PMID: 28522536                                                                                                                              5'-GGAGCGGGAGAAATGGATATG-3'

  Sequence-\                        qRT-PCR primer: SOX10 Forward                                   This paper                                                                                                                                  5'-CCGACCAGTACCCTCACCT-3'
  based reagent                                                                                                                                                                                                                                 

  Sequence-based reagent            qRT-PCR primer: SOX10 Reverse                                   This paper                                                                                                                                  5'- TCAATGAAGGGGCGCTTGT-3'

  Sequence-based reagent            qRT-PCR primer: MYRF Forward                                    This paper                                                                                                                                  5'-ATGGAGGTGGTGGACGAGAC-3'

  Sequence-based reagent            qRT-PCR primer:MYRF Reverse                                     This paper                                                                                                                                  5'-GGCGTCCTCTTTGCCAATGT-3'

  Sequence-\                        qRT-PCR primer: MBP Forward                                     This paper                                                                                                                                  5'-ACACGAGAACTACCCATTATGGC-3'
  based reagent                                                                                                                                                                                                                                 

  Sequence-\                        qRT-PCR primer:\                                                This paper                                                                                                                                  5'-CCAGCTAAATCTGCTGAGGGGA-3'
  based reagent                     MBP Reverse                                                                                                                                                                                                 

  Sequence-\                        qRT-PCR primer:\                                                PMID: 28880149                                                                                                                              5'-GTCCACACCCGCCACC-3'
  based reagent                     Actin Forward                                                                                                                                                                                               

  Sequence-\                        qRT-PCR primer: Actin Reverse                                   PMID: 28880149                                                                                                                              5'-GGCCTCGTCACCCACATAG-3'
  based reagent                                                                                                                                                                                                                                 

  Antibody                          Rabbit polyclonal anti-cleaved Caspase 3                        Cell signaling\                               Cat\# 9661; RRID:[AB_2341188](https://scicrunch.org/resolver/AB_2341188)                      1:500 dilution
                                                                                                    Technology, Danvers, MA, USA                                                                                                                

  Antibody                          Mouse monoclonal anti-CC1                                       Merck Millipore, Billerica, MA, USA           Cat; \# OP80; RRID:[AB_2057371](https://scicrunch.org/resolver/AB_2057371)                    Development: 1:200 dilution;\
                                                                                                                                                                                                                                                Remyelination 1:300 dilution

  Antibody                          rabbit polyclonal anti-FASN                                     Abcam, UK                                     Cat\# Ab22759;\                                                                               1:200 dilution
                                                                                                                                                  RRID:[AB_732316](https://scicrunch.org/resolver/AB_732316)                                    

  Antibody                          Chicken polyclonal anti-GFP                                     Abcam, UK                                     Cat\# Ab13970; RRID:[AB_300798](https://scicrunch.org/resolver/AB_300798)                     1:1000 dilution

  Antibody                          mouse monoclonal anti-ki67                                      Dako Agilent,\                                Cat\# m7249; clone MIB-5; RRID:[AB_2250503](https://scicrunch.org/resolver/AB_2250503)        1:200 dilution
                                                                                                    Santa Clara, CA, USA                                                                                                                        

  Antibody                          rat monoclonal anti-MBP                                         Serotec/BioRad\                               Cat\# MCA409S; RRID:[AB_325004](https://scicrunch.org/resolver/AB_325004)                     Development: 1:200 dilution; Remyelination 1:300 dilution
                                                                                                    Laboratories, Hercules, CA, USA                                                                                                             

  Antibody                          Goat polyclonal anti-Olig2                                      R and D Systems,\                             Cat\# AF2418; RRID:[AB_2157554](https://scicrunch.org/resolver/AB_2157554)                    1:25 dilution
                                                                                                    Minneapolis, MN, USA                                                                                                                        

  Antibody                          mouse monoclonal anti-Olig2                                     Merck Millipore, Billerica, MA, USA           Cat\# MABN50; clone 211F1.1; RRID:[AB_10807410](https://scicrunch.org/resolver/AB_10807410)   1:1000 dilution

  Antibody                          rabbit polyclonal anti-Olig2                                    Merck Millipore, Billerica, MA, USA           Cat\# AB9610; RRID:[AB_570666](https://scicrunch.org/resolver/AB_570666)                      Development: 1:500 dilution; Remyelination 1:400 dilution

  Antibody                          Rabbit monoclonal anti-PDGFRα                                   Cell signaling Technology, Danvers, MA, USA   Cat\# 3174; RRID:[AB_2162345](https://scicrunch.org/resolver/AB_2162345)                      1:500 dilution

  Commercial assay or kit           Click-iT EdU\                                                   Thermo Fisher\                                Cat\# C10337                                                                                  
                                    Assay                                                           Scientific, Waltham, MA, USA                                                                                                                

  Commercial assay or kit           Mouse blocking reagent                                          Vector Laboratories, Burlingame, CA, USA      Cat\# MKB-2213                                                                                

  Commercial assay or kit           Streptavidin/Biotin blocking Kit                                Vector Laboratories, Burlingame, CA, USA      Cat\# SP-2002                                                                                 

  Commercial assay or kit           Qiagen MiniKit (RNeasy Mini Kit)                                Qiagen, Hilden, Germany                       Cat\# 74104                                                                                   

  Commercial assay or kit           TruSeq Stranded mRNA Sample Prep Kit                            Illumina, San Diego, CA, USA                  Cat\# 20020594                                                                                

  Commercial\                       Maxima RT-Kit                                                   Thermo Fisher Scientific, Waltham, MA, USA    Cat\# K1641                                                                                   
  assay or kit                                                                                                                                                                                                                                  

  Chemical compound, drug           Lysolecithin                                                    Sigma-Aldrich, Sant Louis, MO, USA            Cat\# L4129                                                                                   

  Chemical compound, drug           Tamoxifen                                                       Sigma-Aldrich, Sant Louis, MO, USA            Cat\# T5648                                                                                   

  Chemical compound, drug           Lipid standards                                                 Avanti Polar Lipids, Alabaster, AL, USA                                                                                                     

  Software, algorithm               Lipid Data Analyzer software                                    PMID: 29058722                                                                                                                              

  Software, algorithm               Photoshop CS5 or CS6                                            Adobe                                                                                                                                       

  Software,\                        FIJI                                                            ImageJ (<http://imagej.nih.gov/ij/>)                                                                                                        
  algorithm                                                                                                                                                                                                                                     

  Software, algorithm               STAR Aligner(v2.5.1b)                                           PMID: 23104886                                                                                                                              

  Software, algorithm               RSEM (v1.2.22)                                                  PMID: 21816040                                                                                                                              

  Software, algorithm               EdgeR                                                           PMID: 19910308                                                                                                                              

  Software, algorithm               Metacore (vs6.33)                                               Thomson Reuters                                                                                                                             

  Other                             Standard diet (STD)                                             KLIBA NAFAG, Provimi KLIBA, Switzerland       Cat\# 3437                                                                                    

  Other                             High fat diet (HFD)                                             KLIBA NAFAG, Provimi KLIBA, Switzerland       Cat\# 2127                                                                                    
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Contacts for reagents and resource sharing {#s4-1}
------------------------------------------

Requests for further information and reagents may be directed to the corresponding author Ueli Suter (usuter\@biol.ethz.ch). *Fasn*^lox/lox^ mice are available from the Semenkovich laboratory after executing an MTA with Washington University. The *Pdgfr*α*CreERT2* mice are available from the Richardson laboratory after executing an MTA with the University College London. From Jackson Laboratory are available: *Olig2Cre* mice (JAX Stock \#011103) and *Rosa26-loxPstoploxP-YFP* mice (JAX Stock \#006148).

FASN conditional knockout mice {#s4-2}
------------------------------

For developmental studies, mice (*Mus musculus*) homozygous for the fatty acid synthase (*Fasn*) floxed allele ([@bib7]) (Strain of origin: 129X1/SvJ, subsequently crossed with 129X1/SvJ \* C57BL/6 \* DBA) were crossed with mice expressing Cre recombinase under the control of the *Olig2* promoter ([@bib47]) (Strain of origin: C57BL/6) to obtain *Cre*^+^:*Fasn^lox/lox^* mutant mice, and *Fasn^lox/lox^* or *Fasn^lox/wt^* control mice. For experiments assessing recombination frequencies, a *Rosa26-loxPstoploxP-YFP* allele ([@bib50]) (Strain of origin: C57BL/6) was included.

For remyelination studies, mice homozygous for the *Fasn* floxed allele ([@bib7]) (Strain of origin: 129X1/SvJ, subsequently crossed with 129X1/SvJ \* C57BL/6 \* DBA) were crossed with reporter mice homozygous for the *Rosa26-loxPstoploxP-YFP* allele and with mice expressing CreERT2 recombinase, activatable upon tamoxifen injection, under the control of the *Pdgfr*α promoter (*Pdgfr*α*CreERT2)* ([@bib40]) (Strain of origin: C57BL/6). Control mice were *Pdgfr*α*CreERT2^+^:Rosa26-loxPstoploxP-YFP:FASN^wt/wt^* for immunohistochemical analysis and *Rosa26-loxPstoploxP-YFP:FASN^lox/lox^* for electron microscopy analysis. Mutant mice were *Pdgfr*α*CreERT2^+^:Rosa26-loxPstoploxP-YFP:FASN^lox/lox^* for all analyses. All mice were injected with tamoxifen. *Fasn* floxed mice were backcrossed for at least three generations to C57BL/6 background, and *Olig2Cre*, *Rosa26-loxPstoploxP-YFP* and *Pdgfr*α*CreERT2* mice were kept on a C57BL/6 background.

Both male and female mice were used throughout all experiments. Mice were group-caged, kept in a 12 hr light/dark cycle, with water and food provided ad libitum. Littermates and age-matched mice were assigned to experimental groups according to age and genotype. No method of randomization was applied. Animals were fed a standard (STD) (Cat\# 3437, KLIBA NAFAG, Provimi KLIBA, Switzerland) or a high-fat diet (HFD) (Cat\# 2127, KLIBA NAFAG, Provimi KLIBA, Switzerland), as previously described ([@bib35]). Briefly, pregnant females were fed the high fat diet from gestational day 14 until weaning of the pups 3 weeks after birth. Pups were subsequently separated from the mother and kept on a high fat diet until being sacrificed at 40 days of age. Diets content of fatty acids (in percentage) in HFD vs. STD was: C12 0.03 vs. 0.002, C14 0.440 vs. 0.008, C15 0.000 vs. 0.002, C16 8.220 vs. 0.719, C17 0.000 vs. 0.004, C18 4.500 vs. 0.157, C20 0.020 vs. 0.010, C22 0.000 vs. 0.004, C24 0.000 vs. 0.012, C14:1 0.170 vs. 0.001, C16:1c7 1.000 vs. 0.052, C18:1c9 14.120 vs. 1.024, C20:1c9 0.000 vs. 0.013, C22:1c9 0.000 vs. 0.002, C18:2c9c12 4.810 vs. 2.107, C18:3c9c12c15 0.590 vs. 0.212, C20:4(n-6) 0.560 vs. 0.009, C22:5(n-3) 0.000 vs. 0.001. Cholesterol was present in the same percentage (0.030) in both HFD and STD.

Genotypes were determined by PCR on genomic DNA (*Fasn* primers: 5'-Forward GGATAGCTGTGTAGTGTAACCAT-3', Reverse 5'-GGTCACCCAGCAGGAAAGGGC-3'; *Cre* primers: Forward 5'-TTCCCGCAGAACCTGAAGATGTTCG-3', Reverse 5'-GGGTGTTATAAGCAATCCCCAGAAATG-3', *Rosa26-loxPstoploxP-YFP* primers: Forward 5'-AAAGTCGCTCTGAGTTGTTAT-3', Reverse transgenic 5'-GCGAAGAGT TTGTCCTCAACC-3', Reverse wild type 5'-GGAGCGGGAGAAATGGATATG-3'). All animal experiments were performed with the approval and in strict accordance with the guidelines of the Zurich Cantonal Veterinary Office (ref ZH161/2014, ZH090/2017, ZH03/2012, ZH264/2014, ZH207/2017).

Tamoxifen administration {#s4-3}
------------------------

CreERT2-mediated recombination in 8 to 10 week-old mice was induced by a single daily intraperitoneal injection of 2 mg tamoxifen (Cat\# T5648, Sigma-Aldrich, Sant Louis, MO, USA; 20 mg/ml stock solution in sunflower oil containing 10% ethanol) over 5 consecutive days.

Focal spinal cord demyelinating lesions {#s4-4}
---------------------------------------

Four weeks after tamoxifen induction, demyelinated lesions were induced in the ventral funiculus of the thoracic spinal cord at intervertebral level T12/T13 as previously described ([@bib14]). Mice received a preoperative subcutaneous injection of 0.1 mg/kg (of body weight) of buprenorphine (Temgesic solution injectable 0.3 mg/ml, Indivior, Switzerland) in Ringer solution (Braun, Switzerland), and were anesthetized by isoflurane inhalation. A dorsal laminectomy was performed at the T12/T13 level, and the dura pierced with an acupuncture needle. 1 µl of 1% lysolecithin (Cat\# L4129, Sigma-aldrich, Sant Louis, MO, USA) in 1x PBS, pH 7.4, was injected hemilaterally in the ventral funiculus at a rate of 0.5 µl per minute, with a glass needle coupled to a Hamilton syringe, via a three-way micromanipulator (Narishige, Japan). The overlaying musculature was sutured, and wound clips were applied to close the skin above. Animals were allowed to recover on a heating pad at 37°C. Animals received twice daily a subcutaneous injection of 0.1 mg/kg (of body weight) of buprenorphine (Temgesic solution injectable 0.3 mg/ml, Indivior, Switzerland) for two days following the injury. For additional analgesic treatment, animals were supplied with *ad libitum* 0.01 mg/ml buprenorphine (Temgesic solution injectable 0.3 mg/ml, Indivior, Switzerland) in drinking water for three days following injury.

TEM and SEM microscopy {#s4-5}
----------------------

Mice were anaesthetized by terminal intraperitoneal injection of pentobarbital, 10% in saline solution (0.9% NaCl) (Eskonarkon, Streuli Pharma, Switzerland). Mice were intracardially perfused with 0.1M phosphate buffer (PB) pH 7.4, followed by a 2.5% glutaraldehyde/4% paraformaldehyde solution in 0.1M PB. After dehydration through an acetone series, tissues were post-fixed in 2% osmium tetroxide overnight, and embedded in Spurr's resin (Electron Microscopy Sciences, Hatfield, PA, USA). Ultrathin sections were cut on a Leica UC-7 (Leica microsystems, Germany) or a Reichert-Jung Ultra cut E ultramicrotome (Leica microsystems, Germany, 65 nm-thick for transmission electron microscopy (TEM) or 99 nm-thick for scanning electron microscopy (TEM)). Sections transferred onto copper grids with a carbon film (Electron Microscopy Sciences, Hatfield, PA, USA) for TEM or ITO coverslips (Optic Balzers, Germany) for SEM, were counterstained with 2% uranyl acetate and 1% lead citrate. Images were acquired with a Morgagni 268 (FEI) for TEM, for analysis of developmental myelination. For reconstruction of entire lesion areas for the remyelination analysis, SEM was used. Images were acquired using the in-lens detector of a Merlin FEG SEM (Zeiss, Germany) operating at 2 KeV, attached to the ATLAS module (Zeiss, Germany). The entire lesion area was imaged as multiple individual images, with overlap between adjacent ones. Alignment and merging of these images was performed using FIJI (ImageJ) and Photoshop CS5 or CS6 (Adobe). Brightness and contrast of EM images were adjusted for optimal detection of the structures.

Antibodies {#s4-6}
----------

The following antibodies were used: Rabbit anti-cleaved Caspase 3 (IHC 1:500, Cat\# 9661, Cell signaling Technology, Danvers, MA, USA; RRID:[AB_2341188](https://scicrunch.org/resolver/AB_2341188)), mouse anti-CC1 (IHC 1:200 in the analysis of development, 1:300 in the analysis of remyelination, Cat\# OP80, Merck Millipore, Billerica, MA, USA; RRID:[AB_2057371](https://scicrunch.org/resolver/AB_2057371)), rabbit anti-FASN (IHC 1:200, Cat\# Ab22759, Abcam, UK; RRID:[AB_732316](https://scicrunch.org/resolver/AB_732316)), chicken anti-GFP (IHC 1:1000, Cat\# Ab13970, Abcam, UK; RRID:[AB_300798](https://scicrunch.org/resolver/AB_300798)), mouse anti-ki67 (IHC 1:200, Cat\# m7249, clone MIB-5, Dako Agilent, Santa Clara, CA, USA; RRID:[AB_2250503](https://scicrunch.org/resolver/AB_2250503)), rat anti-MBP (IHC 1:200 in the analysis of development, IHC 1:300 in the analysis of remyelination, Cat\# MCA409S, Serotec/BioRad Laboratories, Hercules, CA, USA; RRID:[AB_325004](https://scicrunch.org/resolver/AB_325004)), goat anti-Olig2 (IHC 1:25, Cat\# AF2418, R and D Systems, Minneapolis, MN, USA; RRID:[AB_2157554](https://scicrunch.org/resolver/AB_2157554); biotinylated), mouse anti-Olig2 (IHC 1:1000, clone 211F1.1, Cat\# MABN50, Merck Millipore, Billerica, MA, USA; RRID:[AB_10807410](https://scicrunch.org/resolver/AB_10807410)), rabbit anti-Olig2 (IHC 1:500 in the analysis of development, IHC 1:400 in the analysis of remyelination, Cat\# AB9610, Merck Millipore, Billerica, MA, USA; RRID:[AB_570666](https://scicrunch.org/resolver/AB_570666)), rabbit anti-PDGFRα (IHC 1:500, Cat\# 3174, Cell signaling Technology, Danvers, MA, USA; RRID:[AB_2162345](https://scicrunch.org/resolver/AB_2162345)), donkey anti-chicken Alexa488 (IHC 1:1000, Cat\# 703-545-155, Jackson ImmunoResearch, West Grove, PA, USA; RRID:[AB_2340375](https://scicrunch.org/resolver/AB_2340375)), goat anti-mouse Alexa488 (IHC 1:300, Cat\# A11029, Thermo Fisher Scientific, Waltham, MA, USA; RRID:[AB_138404](https://scicrunch.org/resolver/AB_138404)), donkey anti-mouse Alexa546 (IHC 1:1000, Cat\# A10036, Thermo Fisher Scientific, Waltham, MA, USA; RRID:[AB_2534012](https://scicrunch.org/resolver/AB_2534012)), goat anti-mouse Alexa546 (IHC 1:1000, Cat\# A11030, Thermo Fisher Scientific, Waltham, MA, USA; RRID:[AB_144695](https://scicrunch.org/resolver/AB_144695)), goat anti-mouse Alexa647 (IHC 1:1000, Cat\# A21237, Thermo Fisher Scientific, Waltham, MA, USA; RRID:[AB_1500743](https://scicrunch.org/resolver/AB_1500743)), donkey anti-rabbit Alexa488 (IHC 1:1000, Cat\# A21206, Thermo Fisher Scientific, Waltham, MA, USA; RRID:[AB_2535792](https://scicrunch.org/resolver/AB_2535792)), donkey anti-rabbit Alexa647 (IHC 1:1000, Cat\# A31573, Thermo Fisher Scientific, Waltham, MA, USA; RRID:[AB_2536183](https://scicrunch.org/resolver/AB_2536183)), goat anti-rabbit Alexa546 (IHC 1:1000, Cat\# A11035, Thermo Fisher Scientific, Waltham, MA, USA; RRID:[AB_143051](https://scicrunch.org/resolver/AB_143051)), goat anti-rabbit Alexa594 (IHC 1:300, Cat\# A11012, Thermo Fisher Scientific, Waltham, MA, USA; RRID:[AB_141359](https://scicrunch.org/resolver/AB_141359)), goat anti-rabbit Alexa647 (IHC 1:1000, Cat\# A21244, Thermo Fisher Scientific, Waltham, MA, USA; RRID:[AB_141663](https://scicrunch.org/resolver/AB_141663)), goat anti-rat Alexa647 (IHC 1:300, Cat\# A21247, Thermo Fisher Scientific, Waltham, MA, USA; RRID:[AB_141778](https://scicrunch.org/resolver/AB_141778)), Streptavidin-Alexa647 (IHC 1:1000, Cat\# S21374, Thermo Fisher Scientific, Waltham, MA, USA; RRID:[AB_2336066](https://scicrunch.org/resolver/AB_2336066)).

Immunostaining {#s4-7}
--------------

Cell proliferation was analyzed using the Click-iT EdU Assay (Invitrogen), according to manufacturer's protocol. Mice received a single intraperitoneal injection of EdU (50 mg/Kg of weight) and the tissue of interest was harvested 2 hr after the injection.

Mice were anaesthetized by terminal intraperitoneal injection of pentobarbital, 10% in saline solution (0.9% NaCl) (Eskonarkon, Streuli Pharma, Switzerland). Mice were intracardially perfused with 1x PBS pH 7.4, followed by 4% paraformaldehyde, 5% sucrose in 1x PBS. Dissected tissues were post-fixed in 4% paraformaldehyde, 5% sucrose in 1x PBS overnight at 4°C and cryoprotected in 30% sucrose in PBS for 24 hr at 4°C. Tissues embedded in O.C.T. Tissue Tek (Sakura, The Netherlands) were cut on a cryostat in 10 µm sections with distance between serial sections of 100 µm, and transferred to SuperFrost Plus (Thermo Fisher Scientific, Waltham, MA, USA) coated slides. Slides were stored at −80°C until further use.

For immunostaining, slides were defrosted at room temperature (RT) for at least 30 min and rinsed 3x with 1% Triton X-100 in 1x PBS. Blocking and permeabilization was done with 1% Triton X-100, 10% goat or donkey serum, in 1x PBS for 30 min. Sections were incubated with primary antibodies, diluted in blocking solution, overnight at 4°C. The following day, sections were washed 3 × 10 min with 0.1% Triton X-100 in 1x PBS and incubated with secondary antibodies, diluted in blocking solution, for 2 hr at RT. Sections were washed twice with 0.1% Triton X-100 in 1x PBS, and incubated with 4′,6′-diamidino-2-phenylindole (DAPI) for 10 min. After a last 10 min wash with 1x PBS, sections were coverslipped with ImmuMount (Thermo Fisher Scientific, Waltham, MA, USA). For CC1, cleaved caspase 3, and Ki67 stainings, an antigen retrieval step was added to the above protocol. Briefly, after thawing slides were incubated in a pre-heated antigen retrieval solution in a water bath for 20 min (for analysis of development: Sodium citrate buffer (10 mM Tri-sodium citrate dehydrate, 0.05% Tween-20, pH 6.0) incubated at 95°C, for analysis of remyelination Tris-EDTA buffer (10 mM Trizma Base (Sigma-aldrich, St Louis, MI, USA), 1 mM EDTA, 0.05% Tween-20, pH 9.0) incubated at 86°C). For stainings with mouse anti-CC1 antibody performed for the analysis of remyelination, sections were next incubated with mouse blocking reagent (Cat\# MKB-2213, Vector Laboratories, Burlingame, CA, USA) for 1 hr at RT followed by primary antibody incubation and further processed according to manufacturer's recommendations in 1% Triton X-100 in 1x PBS to prevent cross-reaction of anti-mouse secondary antibodies with endogenous antibodies.

For stainings with biotinylated anti-Olig2 antibody, sections were treated with a Streptavidin/Biotin blocking Kit (Cat\# SP-2002, Vector Laboratories, Burlingame, CA, USA) according to the manufacturer's protocol.

Lipid analysis {#s4-8}
--------------

For lipidomic analysis, myelin from spinal cords dissected from P60 control and mutant mice was isolated by sucrose density gradient centrifugation, as described previously ([@bib25]). Briefly, spinal cords were transferred in suspension buffer (0.3 M sucrose containing as adjuvants 20 mM Tris-HCl pH 7.4, 1 mM EDTA, 1 mM DTT, 100 µM phenylmethylsulfonyl fluoride (PMSF), 10 µg/ml leupeptin, and 10 µg/ml antipain) and tissue disrupted in a glass and stainless steel homogenizer. The homogenate was layered onto a 0.83 M sucrose solution with the same adjuvants, and centrifuged at 75000 g for 30 min at RT. The obtained white band of crude myelin membranes was collected and subjected to three cycles of osmotic shock in 20 mM Tris-HCl pH 7.4 with adjuvants, 1x at 75000 g and 2x at 12000 g at 4°C. Myelin pellets were resuspended in suspension buffer and subjected to a repetition of density centrifugation and osmotic shock. Finally, obtained myelin pellets were resuspended in 0.83 M sucrose solution with adjuvants. This was overlaid with suspension buffer and centrifuged at 75000 g for 30 min at 4°C. The myelin fraction was subjected to a last repetition of osmotic shock and the pellet resuspended in Tris-HCl buffer and immediately frozen in liquid nitrogen. Purified myelin was stored at −80°C until further processing.

Lipid standards were obtained from Avanti Polar Lipids (Alabaster, AL, USA). Analysis of lipid species was performed according to published methods ([@bib15]; [@bib51]). Samples were extracted with methyl tert-butyl ether (MTBE) ([@bib33]). Lipid extracts were evaporated and resuspended in 1 ml chloroform/methanol (1/1; v/v). Each lipid extract was then split for analysis of total fatty acids (350 µl), positive ESI LC-MS/MS (18 µl) and negative ESI LC-MS/MS (18 µl). Lipid extracts for LC-MS/MS analysis were evaporated, spiked with a mix of quantitative LIPID MAPS internal standards and 2 µl of spiked samples were injected onto a Thermo 1.9 µm Hypersil GOLD C8, 100 × 1 mm HPLC column mounted in an Dionex Ultimate 3000 UHPLC instrument (Thermo Fisher Scientific). Data acquisition was performed by Orbitrap Velos Pro (Thermo Fisher Scientific) full scans at a resolution of 100 k and \<5 ppm mass accuracy with external calibration. Nominal mass resolution product ion spectra were acquired in preview mode at the LTQ. A chromatography with Electron Impact Mass Spectrometry (GC-EI/MS) of Total fatty acids (free + esterified) were determined by gas chromatography - electron impact mass spectrometry (GC-EI/MS). Lipid extracts were dried and suspended in 1 ml methanolic NaOH. After 10 min incubation at 80°C, samples were cooled for 5 min on ice. Then, 1 ml BF~3~ was added and incubated for 10 min at 80°C. Fatty acid methyl esters were extracted with 1 ml saturated NaCl and 2 ml hexane. The hexane phase was dried and methyl esters dissolved in 1.5 ml hexane. A Trace-DSQ GC-MS (Thermo Fisher Scientific) equipped with a 30 m column (model TR-FAME, Thermo Fisher Scientific) was used for analysis. Helium was used as carrier gas at a flow of 1.3 ml/min, in split mode, at 250°C injector temperature. Initial oven temperature of 150°C was held for 0.5 min and then temperature was increased to 180°C at a rate of 10 °C/min. This was followed by a further increase to 190°C at a rate of 0.5 °C/min and then increased to 250°C at a rate of 40 °C/min and kept for 3 min. The mass spectrometer was run in EI mode and fatty acids were detected in full scan of m/z 80--400. Source temperature was set to 250°C and the transfer line temperature to 200°C. Internal standards used in LC-MS were (product number, lipid shorthand nomenclature, amount/sample): LM-1100, PE 12:0/13:0, 160 pmol; LM-1102, PE 17:0/20:4, 160 pmol; LM-1103, PE 21:0/22:6, 160 pmol; LM-1104, PE 17:0/14:1, 160 pmol; LM-1302, PS 17:0/20:4, 240 pmol; LM-1300, PS 12:0/13:0, 240 pmol; LM-1304, PS 17:0/14:1, 240 pmol; LM-1000, PC 12:0/13:0, 200 pmol; LM-1002, PC 17:0/20:4, 200 pmol; LM-1003, PC 21:0/22:6, 200 pmol; LM-1004, PC 17:0/14:1, 200 pmol; LM-1601, LPC 17:1, 80 pmol; LM-6002, sphingolipid mix, 120 pmol; LM-1500, PI 12:0/13:0, 320 pmol; LM-1502, PI 17:0/20:4, 320 pmol; LM-1504, PI 17:0/14:1, 320 pmol.

LC = liquid chromatography, ESI = electrospray ionization, MS = mass spectrometry, FT-ICR = Fourier transform ion cyclotron resonance, GC = gas chromatography, EI = electron impact, DSQ = dual stage quadrupole, m/z = mass/ charge number, LM-n = Lipid Maps-ID number, PE = phosphatidylethanolamine, PS = phosphatidylserine, PC = phosphatidylcholine, PI = phosphatidylinositol.

Data were processed by Lipid Data Analyzer software as previously described ([@bib19]), relying on exact mass, retention time and MS/MS spectra. Annotation of lipid species followed the shorthand nomenclature of the International Lipid Classification and Nomenclature Committee ([@bib30]). During lipid extraction procedure, the fraction containing proteins was lyophilized. Proteins were dissolved in lysis buffer (1% Rapigest (Waters/Millipore, Billerica, MA, USA), Tris pH 7.4, 0.1 mM EDTA) and quantified on a Nanodrop Lite (Nanodrop Technologies, Thermo Fisher Scientific) spectrophotometer. Lipid amounts were normalized to the sample total protein content.

Sequencing {#s4-9}
----------

Total RNA was isolated with a Qiagen MiniKit according to manufacturer's protocols, quantity and quality were determined with Nanodrop Lite (NanoDrop Technologies, Thermo Fisher Scientific), Qubit 2.0 Fluorometer (Life Technologies, Carlsbad, CA, USA) and Bioanalyzer 2100 (Agilent, Santa Clara, CA). The TruSeq Stranded mRNA Sample Prep Kit (Illumina, San Diego, CA, USA) was used in the succeeding steps. Briefly, poly-A containing RNA molecules were purified from the total RNA samples (100 ng) using oligo-dT attached magnetic beads. Isolated RNA was reverse-transcribed into double-stranded cDNA, with actinomycin added during first-strand synthesis. The cDNA samples were fragmented, end repaired and polyadenylated before ligation of TruSeq adapters. Fragments containing TruSeq adapters on both ends were selectively enriched with PCR. The quality and quantity of the enriched libraries were validated using Qubit 2.0 Fluorometer and Bioanalyzer 2100. The product is a smear with an average fragment size of approximately 360 bp. The libraries were normalized to 10 nM in Tris-Cl 10 mM, pH 8.5 with 0.1% Tween-20. Sequencing was performed on an Illumina HiSeq 4000 in single end 125 bp mode. The raw reads were first cleaned by removing adapter sequences, trimming low quality ends, and filtering reads with low quality (phred quality \<20). Read-alignment was done with STAR (v2.5.1b). Ensembl genome build GRCm38 was used as reference and gene annotations downloaded on 2015-06-25 from Ensembl. Applied STAR alignment options were: OutFilterType BySJout, outFilter MatchNmin30, outFilter Mismatch Nmax10, outFilter MismatchNoverLmax0.05, alignSJDB overhangMin1, aligns overhangMin8, alignIntron Max1000000, alignMatesGap Max1000000, outFilterMultimapN max50. Quantification of gene level expression was carried out using RSEM (v1.2.22) ([@bib28]). Differential expression was computed using the generalized linear model implemented in the Bioconductor package EdgeR ([@bib41]). To correct for multiple testing, the Benjamini-Hochberg algorithm was applied and adjusted p-values computed. Only significantly differentially expressed transcripts (FDR ≤ 0.05, no fold change threshold) were loaded onto Metacore (vs6.33) for enrichment analysis of GeneOntology processes and Metacore pathways.

qRT-PCR {#s4-10}
-------

Total RNA was isolated with a Qiagen MiniKit according to the manufacturer's protocols; quantity and quality were determined with Nanodrop Lite (NanoDrop Technologies). RNA samples were reverse-transcribed to cDNA with oligo(dT) random primers in the presence of RNaseOUT (Thermo Fisher Scientific, Waltham, MA, USA) with the Maxima RT kit (Thermo Fisher Scientific, Waltham, MA, USA). Targeted sequences were amplified with exon/exon boundary-spanning probes and detected by measurement of SYBRgreen on a LightCycler 480 (Roche, Switzerland). Cp values were determined with the LightCycler 480 software (Roche, Switzerland). Primers used were: SOX10 Forward 5'-CCGACCAGTACCCTCACCT-3', Reverse 5'-TCAATGAAGGGGCGCTTGT-3', MYRF Forward 5'-ATGGAGGTGGTGGACGAGAC-3', Reverse 5'-GGCGTCCTCTTTGCCAATGT-3', MBP Forward 5'-ACACGAGAACTACCCATTATGGC-3', Reverse 5'-CCAGCTAAATCTGCTGAGGGGA-3', Actin Forward 5'-GTCCACACCCGCCACC-3', Reverse 5'-GGCCTCGTCACCCACATAG-3'.

Statistical analysis {#s4-11}
--------------------

All experiments were quantified blindly to the genotype and treatment group. Statistics were analyzed using GraphPad Prism vs6.01. Data were assumed to be normally distributed, but not formally tested. Variance was assumed to be equal between groups of data. No statistical methods were used to predetermine sample size, but our sample sizes are similar than those generally employed in the field. Statistical significance was determined using an unpaired two-tailed two sample Student's t-test for two group comparisons. Multiple groups analysis was performed with analysis of variance (ANOVA) and post-hoc test as detailed in text and figures. Data show mean ±SEM. Significance was set at p\<0.05 \*, p\<0.01 \*\*, p\<0.001 \*\*\*.

Data availability {#s4-12}
-----------------

RNA-sequencing data are available on NCBI's GEO database, accession number GSE112725.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"CNS myelination and remyelination depend on fatty acid synthesis by oligodendrocytes\" for consideration by *eLife*. Your article has been reviewed by Marianne Bronner as the Senior Editor, a Reviewing Editor, and two reviewers. The following individuals involved in review of your submission have agreed to reveal their identity: Teresa Wood (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This study explored the role of fatty acid synthesis in the development of oligodendrocytes and myelin during early postnatal life in mice, and remyelination in the adult CNS. The authors conditionally deleted fatty acid synthase (FASN) from oligodendrocyte progenitors (OPCs) in the developing CNS and found that while this did not impair the proliferation and differentiation of OPCs, it slowed the process of myelination, altered the lipid composition of myelin and disrupted myelin integrity. This delay in myelination was partially reversed by feeding FASN cKO mice a high fat diet. Deletion of FASN from OPCs in the adult CNS similarly impaired the regeneration of myelin sheaths. Together, these findings indicate that de novo fatty acid synthesis is critical for both developmental myelination and remyelination.

Essential revisions:

1\) The authors should quantify the percentage recombination and knockout of FASN in both their developmental model and tamoxifen inducible model. They have the tools to do so and may even have the data to hand in tissue collected. This is particularly important in addressing the apparent diversity in phenotype between optic nerve and spinal cord, and in the difference in phenotypic severity of developmental myelination and remyelination in the spinal cord.

Could such differences be explained simply by recombination efficiency?

If recombination efficiency is similar in spinal cord and optic nerve, the authors should still discuss whether the difference they see there in developmental myelination really reflects intrinsic differences in oligodendrocytes, as suggested, or possibly local differences in astrocyte coupling etc.

2\) Figure 3: EM analysis shows an increase in unmyelinated axons in mutant mice. The authors conclude that FASN is critical for timely onset of myelination. However, the decrease in myelinated axons may not be due to timing of onset, especially since recovery does not occur at P180. Since oligodendrocytes wrap multiple axons per cell, the phenotype could also be attributed to less myelin being produced by each mutant oligodendrocyte and/or fewer myelin sheaths. Another possibility is that the aberrant myelin observed in the mutants reduces their ability to wrap the same number of axon segments. Wording should be altered to reflect other possible conclusions from the EM data.

3\) Figure 3---figure supplement 1: The authors address possible differential dependence on FASN by studying myelin in the spinal cord and optic nerve and conclude that FASN is critical in diverse OL populations. Do the authors have any information from their existing samples on the corpus callosum to strengthen this conclusion?

4\) Figure 8: It is unclear whether the decrease in CC1+ cells at 14 and 21 dpl is due to a deficit in the OPC population, a differentiation deficit, or cell death. TUNEL staining may capture more dying cells than cC3 staining and should be paired with a marker for OPCs and a marker for mature OLs to determine which population is affected. Some information on this could be accomplished on existing tissues. The authors should try to increase their \"n\" for the experiment assessing the contribution of cell death to the phenotypes observed in oligodendrocyte number in mutants during remyelination. It is great that the authors show actual data points, but this reveals huge diversity in Figure 8---figure supplement 3D and E, and I strongly suspect that this experiment would not have had sufficient power to detect a statistically significant increase in cell death, which is indeed suggested by the large fold increase. I appreciate that achieving high statistical power in mammalian in vivo experiments is challenging, but I think this issue needs to be acknowledged. At the very least the authors should discuss this point, lest they run the risk of conveying a potentially misleading false negative.

5\) Figure 8: The observed reduction in recombined OPCs in FASN mutants during remyelination (subsection "Increased dietary intake of lipids can partially rescue lack of fatty acid synthesis by oligodendrocytes") needs to be further discussed. It is interesting that developmental OPCs are unaffected, but adult OPCs show a deficit during remyelination.

6\) Is it possible for the authors to try a high fat diet supplementation following remyelination? This could help assess whether lipid synthesis is a bottleneck to remyelination. Apologies if this has been tested in the past by others, but, if not, this could be a timely opportunity to do so. The authors discuss their surprise in observing a strong phenotype observed for remyelination in the FASN inducible mutants. However, it is possible that the dietary support, or shuttling through astrocytes is actually compromised by the environment of a demyelinating lesion, and it would be interesting to see if high fat diet could help circumvent any such disruption.

10.7554/eLife.44702.030

Author response

> Essential revisions:
>
> 1\) The authors should quantify the percentage recombination and knockout of FASN in both their developmental model and tamoxifen inducible model. They have the tools to do so and may even have the data to hand in tissue collected. This is particularly important in addressing the apparent diversity in phenotype between optic nerve and spinal cord, and in the difference in phenotypic severity of developmental myelination and remyelination in the spinal cord.
>
> Could such differences be explained simply by recombination efficiency?
>
> If recombination efficiency is similar in spinal cord and optic nerve, the authors should still discuss whether the difference they see there in developmental myelination really reflects intrinsic differences in oligodendrocytes, as suggested, or possibly local differences in astrocyte coupling etc.

We have now quantified the recombination percentages using a Cre-dependent reporter allele (since FASN protein was barely detectable in oligodendrocyte progenitor cells). The corresponding data have been added to the revised manuscript (Figure 1---figure supplement 1, Figure 3---figure supplement 1, and Figure 7---figure supplement 1). Accordingly, we have also adjusted the text. However, we have refrained from making potentially over-interpreting statements based on our findings. This choice relates to the highly relevant points raised by the reviewers about potential oligodendrocyte-intrinsic versus local tissue differences in the various regions. Indeed, our evaluation of various myelinated regions was intended to examine whether FASN expression is in principle required for anatomically differently located oligodendrocytes. Thus, the main conclusion of our analysis is that accurate developmental myelination in the spinal cord, the optic nerve, and in the corpus callosum (see answer to point 3 below) depends on FASN expressed by oligodendrocytes. To which extent our findings in the different regions might relate to different environments and physiological contexts, or might be due to potential intrinsic differences between oligodendrocyte lineage cells, remains to be investigated. We have altered the wording in the revised manuscript to reflect these points more clearly. We thank the reviewers for indicating this potential misunderstanding out to us.

> 2\) Figure 3: EM analysis shows an increase in unmyelinated axons in mutant mice. The authors conclude that FASN is critical for timely onset of myelination. However, the decrease in myelinated axons may not be due to timing of onset, especially since recovery does not occur at P180. Since oligodendrocytes wrap multiple axons per cell, the phenotype could also be attributed to less myelin being produced by each mutant oligodendrocyte and/or fewer myelin sheaths. Another possibility is that the aberrant myelin observed in the mutants reduces their ability to wrap the same number of axon segments. Wording should be altered to reflect other possible conclusions from the EM data.

We agree that our wording in this context was not optimal. Thus, we have ameliorated the text to provide a more precise description of the various possibilities, following the valuable suggestions of the reviewers. We thank the reviewers for this input.

> 3\) Figure 3---figure supplement 1: The authors address possible differential dependence on FASN by studying myelin in the spinal cord and optic nerve and conclude that FASN is critical in diverse OL populations. Do the authors have any information from their existing samples on the corpus callosum to strengthen this conclusion?

We have now analyzed the corpus callosum. The corresponding results, revealing that correct myelination in this region is also dependent on FASN expression by oligodendrocytes, have been added to the manuscript (Figure 3---figure supplement 3, and text).

> 4\) Figure 8: It is unclear whether the decrease in CC1+ cells at 14 and 21 dpl is due to a deficit in the OPC population, a differentiation deficit, or cell death. TUNEL staining may capture more dying cells than cC3 staining and should be paired with a marker for OPCs and a marker for mature OLs to determine which population is affected. Some information on this could be accomplished on existing tissues. The authors should try to increase their \"n\" for the experiment assessing the contribution of cell death to the phenotypes observed in oligodendrocyte number in mutants during remyelination. It is great that the authors show actual data points, but this reveals huge diversity in Figure 8---figure supplement 3D and E, and I strongly suspect that this experiment would not have had sufficient power to detect a statistically significant increase in cell death, which is indeed suggested by the large fold increase. I appreciate that achieving high statistical power in mammalian in vivo experiments is challenging, but I think this issue needs to be acknowledged. At the very least the authors should discuss this point, lest they run the risk of conveying a potentially misleading false negative.

We have dedicated substantial efforts to characterize cell death in the oligodendrocyte lineage. Beyond the data included in the manuscript, which consists of the percentage of CC1+ YFP+ cC3+ oligodendrocytes at 11 dpl, we have also assessed:

a\) The population of CC1- YFP+ cC3+ not-differentiated oligodendrocytes and found only one positive cell in one of the animals analyzed (quantified on the same images which generated the data included in the manuscript, at 11 dpl).

b\) Additional time points (10 dpI, 12 dpl; analysis of sections covering the entire lesions in 3 control and 3 i-cMU mice) revealed no YFP+ Cc3+ cells.

We also tested three different TUNEL protocols and assay kits from two independent manufacturer\'s, but unfortunately, none of these methods enabled, in our hands, robust co-staining of TUNEL with antibodies recognizing either YFP or CC1. As the careful comparative analysis of cell death in controls versus mutants mandates the colocalization of apoptosis markers with oligodendrocyte lineage cells and a recombination marker, we are unable to draw firm conclusions from these experiments.

Despite our best efforts, and also due to technical limitations of the experiments and available tools, we consider it unlikely that extending the analysis to increase "n" would provide a satisfying answer in this context. However, as suggested by the reviewer, we acknowledge now this limitation of our analysis explicitly in the revised manuscript.

> 5\) Figure 8: The observed reduction in recombined OPCs in FASN mutants during remyelination (subsection "Increased dietary intake of lipids can partially rescue lack of fatty acid synthesis by oligodendrocytes") needs to be further discussed. It is interesting that developmental OPCs are unaffected, but adult OPCs show a deficit during remyelination.

We discuss this issue now in the revised manuscript in condensed form. One interpretation of our findings is that the observed decrease in CC1+ recombined OLs in mutant animals during remyelination promotes a mild reaction from the aOPCs, potentially with the goal of some compensation. If the recombined cells cannot be sustained and die while differentiating from aOPCs towards myelinating oligodendrocytes, this may cause a slight reduction of the remaining numbers of recombined aOPCs. Alternatively, aOPCs may have intrinsic differences in their dependency on FASN compared to developmental OPCs with regard to survival. We consider this less likely given the low expression of FASN by developmental OPCs and aOPCs.

> 6\) Is it possible for the authors to try a high fat diet supplementation following remyelination? This could help assess whether lipid synthesis is a bottleneck to remyelination. Apologies if this has been tested in the past by others, but, if not, this could be a timely opportunity to do so. The authors discuss their surprise in observing a strong phenotype observed for remyelination in the FASN inducible mutants. However, it is possible that the dietary support, or shuttling through astrocytes is actually compromised by the environment of a demyelinating lesion, and it would be interesting to see if high fat diet could help circumvent any such disruption.

We agree with the reviewers that such studies are highly interesting, including investigations of the conceptual issue of lipid flux from the diet to oligodendrocytes in the context of remyelinating lesions, taking into account shuttling through astrocytes. However, such a study is quite challenging to perform accurately. Mainly due to the complexity of the lesion setting (including potential damage to the blood-CNS barrier), the accurate selection of the experimental conditions and the interpretation of the study will be demanding, not the least since high fat diet supplementation is likely to influence inflammation and potentially other variables. Thus, we feel that such an analysis requires a rather extensive dedicated research project on its own to yield comprehensive and robust results.

[^1]: These authors contributed equally to this work.
